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Abstract  Background: N-acetyl-glutamate synthase (NAGS) deficiency is a rare cause of severe neonatal 
hyperammonemia. Case report: An 8-day old boy, who was born of non-consanguineous Iranian parents by cesarean 
section, was admitted to the neonatal intensive care unit due to poor feeding, unconsciousness, and seizures. High 
Ammonia (920 µmol/L, ref. < 100), high plasma glutamine (1628.6 µmol/L, ref. 410-960) and alanine (1151.5 
µmol/L, ref. 200-600), low plasma citrulline (6.6 µmol/L, ref. 8-47) and arginine (26.7 µmol/L, ref. 20-160), without 
orotic aciduria (orotic acid in urine below detection limit) was revealed in metabolic work-up. Based on these results 
carbamoyl-phosphate synthetase 1 (CPS1) or NAGS deficiency were suspected. The infant was treated by peritoneal 
dialysis, intravenous sodium benzoate, L-arginine, and oral sodium phenylbutyrate and ammonia declined to  
390 µmol/Lafter 10 days. Results: The genetic analysis in the patient and parents confirmed the NAGS deficiency 
with a novel heterozygous maternal missense mutation in exon 5 c.1172T>G (p.Leu391Arg) and the known change 
in exon 6c.1450T>C (p.Trp484Arg) on the paternal allele. Carglumic acid (Carbaglu®, Orphan Europe Recordati, 
Paris, France) was started and ammonia declined to normal (55 µmol/l) after 24 hours, for the first time ever in the 
patient. Based on the severe neurological impairment due to the initial hyperammonemic crisis and difficulties to 
access to the drug in Iran, a decision was made with the parents to stop treatment with carglumic acid (while sodium 
benzoate and sodium phenylbutyrate were continued) and the patient died five days later due to hyperammonemic 
decompensation. Conclusion: NAGS deficiency, although rare, seems to be panethnic. Thus, in case of 
hyperammonemia without orotic aciduria but with low plasma citrulline, NAGS deficiency should be considered 
and a trial with carglumic acid started as early as possible. Our case demonstrates that the prognosis of neonatal 
onset NAGS deficiency largely depends on early recognition and start of therapy. 
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1. Introduction 
N-acetyl-glutamate synthase (NAGS) deficiency 
(MIM#237310) is the rarest form of urea cycle disorders 
(UCDs) [1]. This enzyme produces N-acetyl-glutamate 
(NAG), the essential activator of the first urea cycle 
reaction, catalyzed by carbamoyl-phosphate synthetase 1 
(CPS1), from glutamate and acetyl-CoA [2]. 
NAGS is located in the mitochondrial matrix mainly of 
periportal hepatocytes in the liver and in small intestinal 
cells, as well as with lower expression in few other tissues 
[3,4]. 
The age of clinical presentations can vary from early 
and severe neonatal hyperammonemia to mild adult-onset 
form depending on the severity of enzyme deficiency 
[1,2,5-11]. Near to half of the patients hitherto described 
show an early onset form of disease. Neonatal patients  
 
can present in the first days of life with poor feeding, 
vomiting, unconsciousness, and seizures [6,7,9,13]. 
Patients with late-onset NAGS deficiency, defined as  
an onset outside the neonatal period, may present at  
any age in life with chronic headaches and nausea  
[6,9,13]. The clinical picture of NAGS deficiency is 
indistinguishable from CPS1 deficiency because in both 
conditions plasma citrulline is low, and urinary orotic acid 
is low normal or decreased [5,7,9,14,15,16]. The 
discrimination between these two disorders can only be 
achieved through enzymatic studies [17] or mutation 
analyses [3]. 
To date, 34 patients from 28 families with NAGS 
deficiency have been reported [18]. Here we describe the 
first Iranian case of NAGS deficiency that presented with 
severe neonatal hyperammonemia in the first week of his 
life. This case report underlines the panethnic character of 
NAGS deficiency and the utmost importance of an early 
start of treatment to avoid severe neurological disease. 
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2. Case 
A.M. was born at 39 weeks of gestation by cesarean 
section without any prenatal or perinatal complications. 
He was the second child of Iranian non-related healthy 
parents. His parents lost another child at 13 months of age 
due to hyperammonemia without an exact diagnosis. 
Birth weight and head circumference were 3400 grams 
and 35 cm respectively. The Apgar score was 8/9 and 
physical examinations were completely normal. He was on 
breastfeeding and did not have any problem during the 
first five days of his life. Due to the family history, a full 
metabolic work-up including plasma amino acid and acyl 
carnitine profiles and urinary organic acids assessment has 
been done on the third day of life which was all completely 
normal. 
On the 6th day of life, poor feeding and sleepiness  
was obvious and on the 8th day of life, he developed 
vomiting, lethargy, and respiratory distress and was 
admitted to the neonatal intensive care unit (NICU). On 
admission, he was resuscitated, intubated, and mechanical 
ventilation was started. At that time, ammonia was 
extremely high (920µmol/L, ref. < 100) and metabolic 
acidosis (pH7.21, HCO38.6mmol/L, BE-13.5) was 
revealed. The metabolic acidosis disappeared after 24 hours 
(pH 7.36, HCO324mmol/L) without any intervention apart 
from fluid replacement. Electrolytes, blood glucose and 
liver function tests were normal, and urine ketone bodies 
were negative. 
Oral feeding was stopped on the day of hospitalization 
and 12.5% glucose infusion (120 kcal/kg per day) was 
started. On physical examination at this time, liver was 
palpable (1.5 cm below the costal margin) with truncal 
hypotonia and spasticity in extremities. 
Since a UCD was suspected, intravenous L-arginine 
hydrochloride (600 mg/kg/d) and sodium benzoate as well 
as oral sodium phenyl butyrate (both with loading doses 
500 mg/kg followed 500 mg/kg/d) by nasogastric tube 
was started, but there was no improvement in the clinical 
condition and the plasma ammonia level stayed high 
(701µmol/L). Therefore peritoneal dialysis (PD) was 
initiated on the day of admission. After six days dialysis, 
ammonia decreased to 356 µmol/L and the clinical 
situation improved allowing to stop PD and mechanical 
ventilation on the 6th day after admission. Oral feeding 
with UCD formula was started on the 7th day of 
admission. After three days ammonia levels raised again 
so the neonate became nil per mouth and PD started again 
accompanied by the sameregime of drugs as before. Under 
this regime, ammonia unfortunately never normalized 
(Figure 1 and Table 1). During hospitalization seizures 
occurred which were treated with anti-convulsant drugs, 
however the EEG reported no epileptic discharges. Brain 
ultrasound showed brain edema. 
 
This graph shows the summary of all ammonia levels obtained in the patient and the variation of ammonia level during 
treatment. Unfortunately, parents did not check ammonia between days 90 and 120 due to good clinical situation. 
Figure 1. The variation of ammonia level during treatment 
Table 1. Ammonia and amino acid levels in plasma of patient A. M 
Variable Control Age 
  8 d 11 d 14 d 17 d 27 d 30 d 45 d 50 d 60 d 90 d 92d 120  d 135 d 
Ammonia 17-60 (µmol/L) 920 390 3556 847 352 139 627 475 288 371 55 93 542 
Lactate 0.9-20(mg/dl) 80 15 17 16 16.8 20 29 18 16 - - 14.2 35.3 
Glutamatic acid 10-190(µmol/L) 312 103 254 - 57 66 123 - 315 87 - 87 66 
Glutamine 410-960(µmol/L) 1628 1002 989 - 629.7 674 932 - 504 728 - 414 832 
Citrulline 8-47(µmol/L) 6.6 10 6.9 - 5.2 7 4.3 - 2.7 3.8 - 33 5.9 
Arginine 20-160(µmol/L) 26 28 180§ - 20 83§ 32 - 33 33 - 41 54 
Ornithine 20-135(µmol/L) 27 18 61 - 49 15 39 - 41.7 27 - 40 32 
Alanine 200-600(µmol/L) 1151 600 687 - 249 413 470 - 297 445 - 364 423 
Peritoneal Dialysis  + + - + - - + + - - - - - 
Protein intake (g/kg/d)  - - 0.5 - 0.25 0.5 - - 1 1-1.5 2 2.5 - 
Carglumic acid 
(mg/kg/d divided in three doses)  - - - - - - - - - NCG started 100 100 - 
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Axial T2 weighted MR images from the patient taken at age 4 months illustrate the severe supratentorial brain damage as sequelae from longstanding 
hyperammonemic encephalopathy. While infratentorial structures (Figure 1A) appear normal, both hemispheres are atrophic (Figure 1B,C) but basal 
ganglia are spared from this with only minor atrophy of caudate nuclei (Figure 1C). 
Figure 2. Brain MRI at 4 months of age 
In the metabolic screening, profiles of blood acylcarnitines 
and urinary organic acids were normal and  orotic acid in 
urine was below detection limit. Based on high levels of 
plasma glutamate (312.9 µmol/L, ref. 10-190), glutamine 
(1628.6 µmol/L, ref. 410-960), and alanine (1151.5 µmol/L, 
ref. 200-600) but low citrulline (6.6 µmol/L, ref. 8-47), an 
enzymatic block before ornithine trans-carbamylase 
(OTC), including CPS1 or NAGS deficiency were the 
most probable diagnoses. Genetic analysis confirmed 
NAGS deficiency with a heterozygous novel missense 
mutation in exon 5 of the NAGS genec.1172T>G 
(p.Leu391Arg), and in exon 6 the known change 
c.1450T>C (p.Trp484Arg). The analysis of the parents for 
carrier status confirmed the mutation c.1172T>G in exon 
5 in the mother and c.1450T>C in exon 6 in the father. 
As N-carbamylglutamate(NCG) was not available in 
Iran at that time, treatment with high doses of oral sodium 
phenylbutyrate, sodium benzoate, and L-arginine with 
UCD formula were continued. By this regimen the ammonia 
levels were between 140-370 µmol/Lbut never normalized. 
At three months of age, carglumic acid (Carbaglu®, 
Orphan Europe Recordati, Paris, France) was started with 
100 mg/kg/d divided in three doses. After 24 hours, 
plasma ammonia decreased for the first time in this patient 
to a normal level (55 µmol/L) (Figure 1). Growth parameters 
at that time showed failure to thrive with weight4800 g 
(<5%), head circumference37 cm (<5%), and length 54 
cm (<5%). In the physical exam, he had truncal hypotonia 
with spasticity in extremities, could not control his head 
and did not have normal gaze. Brain CT scan and MRI 
showed marked brain atrophy, bilateral low attenuated 
white matter of centrum of semi-oval and peri-ventricular 
areas (Figure 2). 
As the ammonia reached to the normal level when 
carglumic acid was introduced, the protein content of the 
diet was increased gradually and he was fed with half 
breast milk and half UCD formula. This therapy continued 
for one month and the child did not have any problem. 
Unfortunately, at 4.5 months of age carglumic acid was 
discontinued according to the parents’ decision because of 
severe neurological impairment secondary to the initial 
hyperammonemic crisis, the high costs of the treatment 
and the difficulties to establish this as a long-term therapy. 
When carglumic acid was stopped, ammonia increased 
dramatically to 542 µmol/L and the clinical situation 
worsened rapidly. The child died at4.5months of age after 
five days of discontinuation of carglumic acid due to 
cardiopulmonary arrest despite of high dose sodium 
benzoate, sodium phenylbutyrate, L-arginine hydrochloride 
and protein restriction. 
3. Discussion 
The first case of NAGS deficiency was described in 
1981 by Bachmann et al. [1]. The human NAGS gene  
is located on chromosome 17q21.31 and consists of 7 
exons and 6 introns [3,4,5]. Cloning of the human NAGS 
gene was achieved in 2002 by Caldovic et al. [4] which 
allowed the molecular testing to become the best method of 
diagnosis [5,6,13,18]. Up to now 22 pathogenic mutations in 
the NAGS gene, including 15 missense, 1 nonsense, 4 
frame-shift and 2 splice site mutations have been reported 
[9,18]. In addition, one disease causing mutation has been 
found in the regulatory region [20], but no amino acid 
substitution has been reported either in the mitochondrial 
targeting signal or the variable segment of theNAGS gene 
[21]. 
In our case, we found a heterozygous mutation in exon 
5 c.1172T>G (p.Leu391Arg), and in exon 6 c.1450T>C 
(p.Trp484Arg). To our knowledge, the mutation in exon 5 
is a novel mutation, while the mutation c.1450T>C was 
found before in neonatal onset NAGS deficiency. 
Nearly half of reported patients were homozygous and 
the others were compound heterozygotes [8,23,24]. 
Homozygosity for nonsense or frame-shift mutations will 
cause complete absence of NAGS enzyme or residual 
enzyme activity less than 5%, and most likely results in a 
severe neonatal-onset form [3,4,6,9,16,17,25]. Missense 
mutations, depending on the effect of the single amino-acid 
substitution, may result in either complete or reduced 
residual activity of NAGS, which can cause later and 
milder forms of disease [3,6,16]. However, there is a poor 
genotype-phenotype correlation [3,6,9]. 
The correct diagnosis of NAGS deficiency has a 
significant clinical impact because, unlike in other UCDs 
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requiring intensive treatments including protein-restricted 
diet, medications, dialysis and liver transplantation, 
NAGS deficiency can be effectively treated with  
N-carbamylglutamate, which completely restores ureagenesis 
[14]. This has been also clearly demonstrated in our 
patient, who rapidly showed normal ammonia levels under 
treatment with carglumic acid. Therefore, to confirm the 
diagnosis by mutation analysis and the use of carglumic 
acidin every patient with a high suspicion of this disorder 
are highly recommended [19,27]. 
As we did not have access to this drug in Iran, we could 
not treat our patient immediately after the diagnosis was 
made (or even earlier upon suspicion of the diagnosis) so 
he experienced long time hyperammonemia which caused 
severe brain damage and neurological sequels. As soon as 
the drug became available, it was started, and ammonia 
levels decreased dramatically. He did not have any 
hyperammonemic episode while under carglumic acid, 
whereas before he never had normal ammonia levels 
despite full doses of sodium benzoate, sodium phenylbutyrate, 
L-arginine, and restricted protein diet. Unfortunately, 
severe brain damage secondary to hyperammonemic crises 
indicated a poor outcome thus limiting the benefits from 
this therapy which was also difficult to establish as long-
term therapy and very costly, so the parents decided to 
withdraw the treatment despite of the good biochemical 
response. As expected, ammonia levels increased rapidly 
after discontinuation of carglumic acid and the patient 
died at 4.5 months of age due to cardiopulmonary arrest 
after hyperammonemic crisis. 
It is very likely that if the patient was diagnosed and 
treated in his first episode of hyperammonemia in neonatal 
period, the outcome would have been entirely different. 
Following the diagnosis of this patient, the drug has 
recently been registered by the ministry of health (MOH) 
and we hope to not confront a similar situations in next 
cases. To prevent similar conditions and to achieve an 
improved outcome it is required to arrange international or 
regional collaborations in the Middle East to ensure early 
diagnosis and treatment of patients with rare diseases that 
require immediate management. 
Although the treatment of our patient was started too 
late, we fortunately will be able to help this family in a 
future pregnancy by offering prenatal diagnosis (PND), 
and hereby prevent a similar catastrophic situation.  
In conclusion NAGS deficiency is an exceedingly rare 
disease, but it is the only UCD that can be effectively 
treated with a drug. Therefore, it has been suggested that 
all hyperammonemic newborns with a suspected diagnosis 
of a UCD especially with low plasma citrulline and absent 
or low urinary orotic acid, should receive a therapeutic 
trial of NCG, which may provide a life-saving therapeutic 
option for patients with NAGS deficiency [8,24,27]. 
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